Tech Company Financing Transactions

Amylyx Pharmaceuticals Funding Round

Amylyx Pharmaceuticals secured a $135 million Series C financing round on 7/21/2021. Investors included Viking Global Investors, 683 Capital and Alpha Wave Ventures.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

43 Thorndike St.
Cambridge, MA 02141
USA

Phone

Undisclosed

Website

www.amylyx.com

Email Address

[email protected]

Overview

Amylyx is an IND-enabling stage biopharmaceutical company dedicated to providing innovative, disease-modifying solutions for neurodegenerative diseases. We have a highly creative and motivated team focused on streamlined clinical development and drug discovery.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Joshua Cohen

        

Chief Executive Officer

Justin Klee

        

Chief Financial Officer

James Frates

        

Chief Medical Officer

Patrick Yeramian

        

Chief Scientific Officer

Kent Leslie

        

VP - Bus. Development

Margaret Olinger

        

VP - Human Resources

Debra Canner

        

Browse more venture capital transactions:

Prev: 7/21/2021: Titan Global Capital Management venture capital transaction
Next: 7/21/2021: Inkbit venture capital transaction

Share this article

About Database of VC Transactions

We record every notable VC transaction. VC transactions reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary